جدول الترويج Cybin Inc.
الجدول الزمني المتقدم
رسم بياني بسيط
عن الشركة Cybin Inc.
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in in preclinical stage to treat neuroinflammation. مزيد من التفاصيل| IPO date | 2019-09-13 |
|---|---|
| ISIN | CA23256X1006 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | cad |
| Сайт | https://www.cybin.com |
| Цена ао | 7.01 |
| تغير السعر يوميا: | -4.27% (7.02) |
|---|---|
| تغير السعر في الأسبوع: | -8.07% (7.31) |
| تغير السعر شهريا: | -18.64% (8.26) |
| تغير السعر خلال 3 أشهر: | -26.56% (9.15) |
| تغير السعر على مدى ستة أشهر: | -24.41% (8.89) |
| تغير السعر سنويا: | +1 501.53% (0.4196) |
| تغير السعر على مدى 3 سنوات: | +772.73% (0.77) |
| تغير السعر على مدى 5 سنوات: | +3 307.71% (0.1972) |
| تغير الأسعار منذ بداية العام: | -23.81% (8.82) |
|
|
الاستهانة
|
كفاءة
|
|||||||||||||||||||||||||||||||||||||
توزيعات الأرباح
|
واجب
|
دافع النمو
|
|||||||||||||||||||||||||||||||||||||
| المؤسسات | مقدار | يشارك, % |
|---|---|---|
| Point72 Asset Management, L.P. | 30061112 | 4.04 |
| Anson Funds Management LP | 8924494 | 1.2 |
| Alyeska Investment Group, L.P. | 5683196 | 0.76 |
| CVI Holdings, LLC | 5225262 | 0.7 |
| AdvisorShares Investments, LLC | 1859181 | 0.25 |
| PDS Planning, Inc | 1153120 | 0.16 |
| Propel Bio Management, LLC | 850000 | 0.11 |
| Simplify Asset Management, Inc. | 500000 | 0.07 |
| FNY Investment Advisers, LLC | 402000 | 0.05 |
| Lewis Asset Management, LLC | 282000 | 0.04 |
| مشرف | مسمى وظيفي | قسط | سنة الميلاد |
|---|---|---|---|
| Mr. Eric So L.L.B. | Co-Founder, President & Executive Chairman | 458.88k | 1976 (49 سنين) |
| Mr. Douglas L. Drysdale | Chief Executive Officer | 613.44k | 1970 (55 سنين) |
| Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director | 458.88k | 1989 (36 سنين) |
| Mr. Greg Cavers | Chief Financial Officer | 242.09k | 1971 (54 سنة) |
| Mr. Aaron Bartlone | Chief Operating Officer | 379.12k | 1967 (58 سنين) |
| Mr. John Kanakis | Co-Founder | 704.03k | 1981 (44 سنة) |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer | N/A | 1960 (65 سنين) |
| Ms. Lori Challenger | Chief Compliance, Ethics & Administrative Officer | N/A | |
| Mr. Gabriel Fahel | Chief Legal Officer & Corporate Secretary | N/A | 1976 (49 سنين) |
| Mr. George Tziras | Chief Business Officer & Director | 1981 (44 سنة) |
عنوان: Canada, Toronto, 100 King Street West - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://www.cybin.com
موقع إلكتروني: https://www.cybin.com
